Incentivising life sciences innovation

It’s not just children who are home schooling and learning new lessons in this pandemic! Many of us, locked down in our homes, are learning to take nothing for granted. Already we know that there will be no V-shaped recovery and that yesterday's threatening digital technologies are now saving lives by enabling (some of us) to work together safely, productively, and remotely.
Working online with leading law firm Pinsent Masons, the Industry Forum meeting this week addressed the highly topical subject of ‘Incentivising Innovation in Life Sciences'. Daniel Zeichner MP, Chair of the All-Party Parliamentary Group for Life Sciences kicked off the meeting and David Rosenberg, retired GSK Vice-President for Intellectual Property policy responded. The meeting was moderated by Nicole Jadeja, a life sciences partner in Pinsent Masons.
With representatives of many leading leading life sciences companies participating, ideas on improving IP laws were discussed as well as hopes for coordinated international actions to prepare better for future health emergencies. In Q&A the need for different funding and pricing models for different diseases and markets was discussed. The Industry Forum is researching this area for future meetings and would welcome industry input.

For more information on this event